Skip to main content
OpenTrials
Recruiting

NCT Number: NCT00556530

Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome

22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people. This study will analyze DNA from people with 22q11.2 deletion syndrome to identify genetic variations that may affect the severity of the disorder.

Recruiting

Interested in participating?

Request Info

Key information

About this study

22q11.2 deletion syndrome is a disorder caused by the deletion of a small piece of chromosome 22. Most people with this disorder are missing a sequence of about 3 million DNA building blocks on chromosome 22 within each cell. This disorder affects many areas of the body. People with 22q11.2 deletion syndrome may have heart defects, immune deficiency, kidney abnormalities, hearing loss, and cleft palate or other facial deformities. Many children experience developmental delays and learning disabilities, and they have an increased risk of developing mental illnesses, including schizophrenia, depression, anxiety, and bipolar disorder. All people with 22q11.2 deletion syndrome are missing the same sequence of DNA, but the severity of this disorder varies widely; some people are diagnosed with multiple health and developmental problems, while others experience very few symptoms. In some people, the symptoms may be so minimal that they are not even aware they have 22q11.2 deletion syndrome. This study will examine genetic material-either from blood or saliva-among people with 22q11.2 deletion syndrome. Participants will attend one study visit and undergo either blood or saliva collection. By analyzing the DNA sequences of participants, the study will aim to identify any genetic variations that may affect the severity of 22q11.2 deletion syndrome.

NOTE: Each clinical site is under the governance of its own Institutional Review Board and discretionary clinicaltrials.gov registration.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has 22q11 deletion of 3 megabases (Mb)

Exclusion criteria

  • Has 22q11 deletion smaller than 3 Mb or no deletion

Study contacts

Contact information is provided by the study sponsor or research team.

Bernice E. Morrow, PhD

CONTACT

[email protected]

914-329-4653

Sponsors and collaborators

Lead sponsor

Albert Einstein College of Medicine

Other

Collaborators

  • Bambino Gesù Children's Hospital IRCCS
  • Cardiff University
  • Children's Hospital of Philadelphia
  • KU Leuven
  • Maastricht University
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute on Aging (NIA)
  • Tel Aviv University
  • The Coriell Institute
  • Universidad del Desarrollo
  • University of California, Los Angeles
  • University of Geneva, Switzerland
  • University of Toronto

Registry information

Official study title

Genetic Modifiers of 22q11.2 Deletion Syndrome

Important dates

Study start
2016
Primary completion
2029
Study completion
2029
First posted
Nov 12, 2007
Registry last updated
Jul 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.